Correction: M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity [0.03%]
纠正：M2巨噬细胞通过上调PI3K-AKT途径活性支持巨核系生成，而非M1巨噬细胞
Hong-Yan Zhao,Yuan-Yuan Zhang,Tong Xing et al.
Hong-Yan Zhao et al.
Sex difference in human diseases: mechanistic insights and clinical implications [0.03%]
人类疾病的性别差异：机制和临床意义的见解
Yuncong Shi,Jianshuai Ma,Sijin Li et al.
Yuncong Shi et al.
Sex characteristics exhibit significant disparities in various human diseases, including prevalent cardiovascular diseases, cancers, metabolic disorders, autoimmune diseases, and neurodegenerative diseases. Risk profiles and pathological ma...
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control [0.03%]
新兴和再现的传染病：全球趋势及其预防控制新策略
Shen Wang,Wujian Li,Zhenshan Wang et al.
Shen Wang et al.
To adequately prepare for potential hazards caused by emerging and reemerging infectious diseases, the WHO has issued a list of high-priority pathogens that are likely to cause future outbreaks and for which research and development (R&D) e...
Metabolic inflexibility of mitochondria: beneficial for the fitness of regenerating liver cells [0.03%]
线粒体代谢刚性利于再生肝细胞的增殖及分化
Josef Ecker,Sarah Brunner,Klaus-Peter Janssen
Josef Ecker
Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a "shock and kill" strategy for ART-free virological control: a phase II single-arm study [0.03%]
抗PD-L1抗体ASC22联合组蛋白脱乙酰酶抑制剂氯達敏作为“唤醒与杀死”的策略实现停用ART的病毒学控制：一项二期、单臂研究
Luling Wu,Zhihang Zheng,Jingna Xun et al.
Luling Wu et al.
The combination of ASC22, an anti-PD-L1 antibody potentially enhancing HIV-specific immunity and chidamide, a HIV latency reversal agent, may serve as a strategy for antiretroviral therapy-free virological control for HIV. People living wit...
A new paradigm for generating high-quality cardiac pacemaker cells from mouse pluripotent stem cells [0.03%]
一种通过从小鼠多能干细胞生成高质量心脏起搏器细胞的新范式
Zheyi Lin,Bowen Lin,Chengwen Hang et al.
Zheyi Lin et al.
Cardiac biological pacing (BP) is one of the future directions for bradyarrhythmias intervention. Currently, cardiac pacemaker cells (PCs) used for cardiac BP are mainly derived from pluripotent stem cells (PSCs). However, the production of...
Elimination of mutant SWI/SNF complexes by protein quality control: new opportunities targeting aggressive rhabdoid tumours [0.03%]
蛋白质质量控制消除突变型SWI/SNF复合物：治疗侵袭性肿瘤的新策略
Andreas Krämer,Stefan Knapp
Andreas Krämer
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study [0.03%]
特瑞普利单抗联合大剂量甲氨蝶呤、替莫唑胺及奥妥珠单抗治疗原发中枢神经系统淋巴瘤的Ⅱ期临床研究
Zhiyong Zeng,Apeng Yang,Jingke Yang et al.
Zhiyong Zeng et al.
Primary central nervous system lymphoma (PCNSL) is a rare and frequently fatal lymphoma subtype. The programmed death-1 (PD-1) pathway has emerged as a potential therapeutic target, but the effectiveness of PD-1 antibody sintilimab in combi...
"Clone-specific" antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers [0.03%]
“克隆特异性”抗体-药物偶联物：T细胞肿瘤治疗的创新策略
Dennis Jungherz,Philipp Lückemeier,Marco Herling
Dennis Jungherz
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation [0.03%]
特瑞普利单抗治疗聚合酶ε/δ(POL E/D)突变的晚期实体瘤的II期临床研究
Ying Jin,Run-Jie Huang,Wen-Long Guan et al.
Ying Jin et al.
Patients carrying mutations in polymerase epsilon/polymerase delta have shown positive responses to immune checkpoint inhibitors. Yet, prospective trials exploring the efficacy in those with polymerase epsilon/polymerase delta mutations are...